¸ß¼ØÑªÖ¢ÐÂÒ©Àû±¶×¿®ÕýʽÉÏÊÐ

·¢²¼Ê±¼ä£º2020-04-08 21:09:18 À´Ô´£º

ÉϺ£2020Äê4ÔÂ10ÈÕ /ÃÀͨÉç/ -- °¢Ë¹Àû¿µÖйú½ñÈÕÐû²¼ÆäÐÂÐͿڷþ½µ¼ØÒ©ÎïÀû±¶×¿®£¨Í¨ÓÃÃû£º»·¹èËáï¯ÄÆÉ¢£©ÒÑÔÚÖйúÕýʽÉÏÊУ¬ÎªÎÒ¹ú¸ß¼ØÑªÖ¢»¼Õß´øÀ´¿ìËÙ¡¢³¤Ð§ÇÒÄÍÊÜÐÔÁ¼ºÃµÄ½µ¼Ø¿Ø¼ØÐÂÑ¡Ôñ¡£

¸ß¼ØÑªÖ¢ÐÂÒ©Àû±¶×¿®ÕýʽÉÏÊÐ
»·¹èËáï¯ÄÆÉ¢ÉÏÊÐÒÇʽ

½ü60ÄêÎÞÐÂÒ©£¬ÎÒ¹ú¸ß¼ØÑªÖ¢ÖÎÁÆÃæÁÙ¾Þ´óÌôÕ½

¸ß¼ØÑªÖ¢ÊÇÂýÐÔÉöÔಡ£¨CKD£©¼°ÐÄÁ¦Ë¥½ß£¨HF£©»¼Õß×î³£¼ûµÄ²¢·¢Ö¢Ö®Ò»¡£ÎÒ¹úÔ¼ÓÐ1.6ÒÚCKD»¼Õߣ¬ÆäÖнüËijÉÖÕÄ©ÆÚCKD»¼ÕßËÀÓÚÐÄÂÉʧ³£»òÐÄÔàÖèÍ££¬¶øî¾»¼¸ß¼ØÑªÖ¢»¼ÕßµÄÈ«ÒòËÀÍöÂÊÊÇÕý³£Ñª¼ØÈËȺµÄ26±¶[1]£¬ÑÏÖØ¸ß¼ØÑªÖ¢»¼ÕßµÄËÀÍöÂʿɸߴï30%[2]¡£

¹ã¶«Ê¡ÈËÃñÒ½ÔºÔº³¤ÓàѧÇå½ÌÊÚ±íʾ£º¡°¸ß¼ØÑªÖ¢¼«Ò×·´¸´£¬ÑÏÖØÎ£º¦»¼ÕßÉúÃü°²È«¡£¹ýÈ¥¶àÄêÀ´£¬ÎÒ¹úÁÙ´²Ò½ÉúΪÖÎÁƸ߼ØÑªÖ¢ÉÏÏÂÇóË÷£¬Ï£ÍûÄÜΪ»¼ÕßѰÇó¿ìËÙÓÐЧÇҿɳ¤ÆÚά³ÖµÄÖÎÁÆ·½°¸£¬È´Ê¼ÖÕ¿àÎÞÁ¼²ß¡£¡±

ÒÔÍù£¬Õë¶Ô¸ß¼ØÑªÖ¢µÄÁÙ´²³£ÓÃÖÎÁÆ·½°¸°üÀ¨´«Í³¾²ÂöÒ©ÎïÖÎÁÆ¡¢¿Ú·þ½µ¼ØÊ÷Ö¬ºÍ͸ÎöÖÎÁÆ¡£ÕâЩÖÎÁÆÊֶθ÷×Ô´æÔÚ¾ÖÏÞÐÔ£¬ÀýÈ磺¾²ÂöÒ©ÎïÖÎÁƲ»ÄÜÈ¥³ýÌåÄÚ¶àÓàµÄ¼ØÀë×Ó£¬ÁÆÐ§Î¬³Öʱ¼ä½Ï¶Ì[3]£»½µ¼ØÊ÷Ö¬ÆðЧÂý£¬ÇÒ¿ÉÄܵ¼ÖÂÑÏÖØµÄ賦µÀ²»Á¼·´Ó¦[4]£»Í¸ÎöÖÎÁÆ´æÔÚ¸´·¢µÄ·çÏÕ£¬¶ÔÒ½ÁÆ×ÊÔ´Õ¼Óôó£¬ÇÒ͸ÎöºóѪ¼ØË®Æ½»ØÉý[5]¡£

´ËÍ⣬CKDºÍHF³£¹æÓÃÒ©£¬ÈçÉöËØ-Ѫ¹Ü½ôÕÅËØ-È©¹ÌͪϵͳÒÖÖÆ¼Á£¨RAASi£©£¬Ò²Îª¿ØÖÆÑª¼ØË®Æ½´øÀ´ÌôÕ½¡£Öйúҽѧ¿ÆÑ§Ôº¸·ÍâÒ½ÔºÐÄÁ¦Ë¥½ßÖÐÐÄÖ÷ÈÎÕŽ¡½ÌÊÚ±íʾ£º¡°RASSiÖÎÁÆ¿ÉÄÜÔì³ÉÐÄË¥»¼ÕßѪ¼ØË®Æ½Éý¸ß£¬µ«Èç¹û¼õÁ¿»òÍ£Óã¬Ôò¿ÉÄܵ¼ÖÂÐÄË¥¶ñ»¯ºÍËÀÍöÂÊÔö¼Ó£¬Õâ¾ÍÈÃÖÎÁÆÏÝÈëÁË¡®Á½ÄѾ³µØ¡¯¡£Òò´Ë¼±ÐèÕÒµ½¼ÈÄÜÓÐЧ¿ØÖÆÑª¼Ø£¬ÓÖ²»Ó°ÏìÐÄË¥³£¹æÖÎÁƵĽâ¾ö·½°¸¡£¡±

´´ÐÂÀë×Ó¡°²¶»ñ¡±¼¼Êõ£¬³É¾Í¡°¿Ø¼ØÀûÆ÷¡±

»·¹èËáï¯ÄÆÉ¢ÊÇÒ»ÖÖ²»ÈÜÓÚË®µÄ»¯ºÏÎ²ÉÓô´ÐÂÀë×Ó²¶»ñ¼¼Êõ£¬¶Ô¼ØÀë×Ó¾ßÓиßÑ¡ÔñÐÔ£¬ÇÒ²»±»ÈËÌåÎüÊÕ»ò´úл£¬Í¨¹ý·à±ãÅųöÌåÍ⣬´Ó¶ø´ïµ½¿ìËÙ½µ¼Ø²¢½«Ñª¼Ø³¤ÆÚÎȶ¨ÔÚ°²È«·¶Î§¡£

È«ÇòÁÙ´²ÊÔÑé½á¹ûºÍÒ»ÏîÖйúҩЧѧÑо¿±íÃ÷£¬»·¹èËáï¯ÄÆÉ¢ÔÚ·þÒ©ºó1Сʱºó¼´¿ªÊ¼ÆðЧ[6]£¬´ïµ½Õý³£Ñª¼ØË®Æ½µÄÖÐλʱ¼äÊÇ2.2Сʱ[7]£¬48СʱÄÚ98%µÄ»¼Õß´ïµ½Õý³£Ñª¼ØË®Æ½[8]¡£½ü¾Å³É»¼ÕßÖÎÁÆ1Äêά³ÖѪÇ弨µÍÓÚ5.1mmol/L[9]£¬ÇÒ³¤ÆÚÄÍÊÜÐÔÁ¼ºÃ£¬ÎÞÑÏÖØ²»Á¼·´Ó¦[6],[7],[10]¡£

»·¹èËáï¯ÄÆÉ¢Òò¶ÀÌØµÄ×÷ÓûúÖÆÓëÁÙ´²ÁÆÐ§£¬¿É°ïÖú¸ß¼ØÑªÖ¢»¼Õß½â¾öδ±»Âú×ãµÄÖÎÁÆÐèÇó£¬2019ÄêÉϰëÄê±»¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ£¨CDE£©ÄÉÈëµÚ¶þÅú¡¶ÁÙ´²¼±Ðè¾³ÍâÐÂÒ©Ãûµ¥¡·£¬ÓèÒÔÓÅÏÈÉóÆÀÉóÅú£¬²¢ÓÚ2019Äê12Ô»ñµÃÖйú¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾Ö£¨NMPA£©µÄÉÏÊÐÅú×¼£¬ÓÃÓÚÖÎÁƳÉÈ˸߼ØÑªÖ¢¡£

ÓàѧÇå½ÌÊÚ±íʾ£º¡°»·¹èËáï¯ÄÆÉ¢µÄ»ñÅú´òÆÆÁËÎÒ¹ú³ÉÈ˸߼ØÑªÖ¢60ÄêÎÞÐÂÒ©µÄÀ§¾Ö¡£Èç½ñ°éËæ×ÅÕâ¿î´´ÐÂÒ©ÎïµÄÉÏÊУ¬ÏàÐÅÎÒ¹ú¸ß¼ØÑªÖ¢ÖÎÁƵÄ·¾¶½«Òò´Ë¸Äд£¬Îª¸ü¶àµÄ»¼Õß´øÀ´¸£Òô¡£¡±

Éî¸ûÉö²¡ÁìÓò£¬ÖúÁ¦½¡¿µÖйú

ÖйúCKDµÄ·¢²¡ÂÊÒѸߴï10.8%[11]£¬Ã¿10¸ö³ÉÄêÈ˾ÍÓÐÒ»ÈË»¼ÓÐCKD¡£³ýÁ˼²²¡±¾ÉíµÄÖÎÁÆ£¬¶Ô²¢·¢Ö¢µÄ¿ØÖÆÒàÊÇØ½´ýÂú×ãµÄÁÙ´²ÐèÇó¡£Ãæ¶ÔÈÕÒæÔö³¤µÄ¼²²¡ÐèÇ󣬰¢Ë¹Àû¿µ²»¶Ï¼Ó´óÔÚÉöÔಡÁìÓòµÄ´´ÐÂͶÈ룬³ÖÐøÍÆ¶¯ÂýÐÔÉöÔಡ¹æ·¶»¯ÕïÁƺÍÈ«²¡³Ì¹ÜÀí¡£

2018Ä꣬°¢Ë¹Àû¿µºÍ·©²©½øºÏ×÷¿ª·¢µÄ¹ú¼Ò1Àà´´ÐÂÒ©¡¢È«ÇòÊ׸ö¿Ú·þHIF-PHI--ÂÞɳ˾Ëû½ºÄÒÔÚÖйú»ñÅú£¬²¢ÓÚ2019Äêµ×±»ÄÉÈëÒ½±£¡£Ê±¸ôÒ»Ä꣬»·¹èËáï¯ÄÆÉ¢ÔÚÖйúµÄ»ñÅúÉÏÊÐΪ°¢Ë¹Àû¿µÉöÔಡÖÎÁÆÁìÓòÔÙÌíÖ§Öù£¬Ò²Ó¡Ö¤Á˰¢Ë¹Àû¿µÉî¸ûÖйúÂýÐÔÉöÔಡÁìÓò¡¢¼ÓËÙÈ«ÇòÇ°ÑØ´´ÐÂÖÎÁÆÊֶλݼ°Öйú»¼ÕߵľöÐÄ¡£

°¢Ë¹Àû¿µÖйú×ܾ­ÀíÀµÃ÷¡±íʾ£º¡°°¢Ë¹Àû¿µÊ¼ÖÕ¼á³ÖÒÔ»¼ÕßΪÖÐÐÄ£¬ÎªÂú×ãÖйú»¼Õ߯ÈÇеÄÖÎÁÆÐèÇ󣬳ÖÐøÒý½øÈ«Çò´´ÐÂÒ©Îï¡£ÖйúÂýÐÔÉöÔಡ»¼Õß»ùÊý¾Þ´ó¡¢Ø½Ðè´´ÐÂÖÎÁƺ͹ÜÀí·½°¸£¬ÎÒÃÇÕýЯÊÖ¸÷·½ºÏ×÷»ï°é£¬¹²½¨Ò»Ì廯´´Ð½â¾ö·½°¸£¬²¢¼á³Ö´òÔìÉö¿ÆÁìÓò×îרҵµÄÐÐҵƽ̨£¬Íƶ¯ÖйúÂýÐÔÉöÔಡ¹æ·¶»¯ÖÎÁƽø²½£¬ÎªÊµÏÖÉöÔಡ»¼Õß×·ÇóÃÀºÃÉú»îµÄÔ¸Íû¶ø¹²Í¬Å¬Á¦¡£¡±

[1]Wang et al. Chin J Nephrol, August 2018, Vol. 34, No.8

[2]Dunn J, et al. The burden of hyperkalaemia in patients with cardiovascular and renal disease. Am J Manag Care. 2015;21(15
Suppl)307-15.

[3]CLINICAL PRACTICE GUIDELINES£ºTREATMENT OF ACUTE HYPERKALAEMIA IN ADULTS. The Renal Association.
2014; Viera AJ, et al American Family Physician Volume 92, Number 6 September 15, 2015

[4]Watson MA et al. Am J Kid Dis. 2012; 60(3): 409-16.

[5]Dunn JD,et al. Am J Manag Care 2015,21(15 Suppl):s307-15.

[6]AstraZeneca. Lokelma Prescribing Information. December 2019.

[7]Fishbane S, et al. Clin J Am Soc Nephrol. 2019 Jun 7;14(6):798-809. doi: 10.2215/CJN.12651018. Epub 2019 May 20.

[8]National Kidney Foundation. Clinical Update on Hyperkalemia. 2014. Accessed 17 December
2019.https://www.kidney.org/sites/default/files/02-10-6785_HBE_Hyperkalemia_Bulletin.pdf

[9]Spinowitz BS et al.Clin J Am SocNephrol.2019:14:798-809

[10]Ash S, et al. A Phase 2 Study on the Treatment of Hyperkalemia in Patients with Chronic Kidney Disease Suggests that the
Selective Potassium Trap, ZS-9, is Safe and Efficient. Kidney Int. 2015; 88, 404-411.

[11]ÕÅ·ϼ£¬Íõ·¼£¬ÍõÀòµÈ£¬ÖйúÂýÐÔÉöÔಡ»¼²¡Âʵĺá¶ÏÃæµ÷²é£¬ÖлªÄÚ¿ÆÔÓÖ¾£¬2012,51:570

Ïà¹ØÈÈ´ÊËÑË÷£º
¹ØÓÚÎÒÃÇ ÁªÏµÎÒÃÇ ÈËÔ±²éѯ ÃâÔðÉùÃ÷ ÓÑÇéÁ´½Ó ¹óÖÝÍøLOGO ¹ã¸æ¿¯Àý ±¾Õ¾ÓòÃû °Ù¶ÈÐÂÎÅ